Research & Development

With the help of our network of partners, we are developing solutions for some of the most pressing global health care problems today.



Hospital admission testing of resistant pathogens using Laser PCR® (Acronym: KAREL)
Problem: Methicillin-resistant Staphylococcus aureus (MRSA) bacteria are resistant to many antibiotics and can cause a variety of problems ranging from skin infections and sepsis, to pneumonia and bloodstream infections.

Solution: A Laser PCR-based MRSA detection assay for the Point of Care that provides ultrafast testing of patients entering the hospital system, in order to reduce unnecessary patient isolation and prevent proliferation of infection within the hospital environment.
This project is co-funded by the German Federal Ministry of Education and Research (BMBF).



Rapid test for antibiotic-resistant Gram-negative pathogens (Acronym: SAGE)
Problem: Gram-negative bacteria are increasingly resistant to most available antibiotics.
Solution: An ultrafast sample to result platform with highly multiplexed assays to provide specific and rapid detection of resistance in multi-drug resistant Gram-negative bacteria (MDRGN), to allow rapid monitoring of infections, as well as investigation and containment of outbreaks.
This project is co-funded by the German Federal Ministry of Education and Research (BMBF).



Point-of-Care implementation of TB testing with ultrafast Local Heating PCR (PITBUL)
Problem: Tuberculosis (TB) is one of the top 10 causes of death worldwide. TB is caused by bacteria (Mycobacterium tuberculosis) that most often infects the lungs.
Solution: PITBUL is an international research project established to help end Tuberculosis (TB) by developing an ultrafast test that can diagnose the disease in minutes. The goal of the project is to use cutting edge technology to create an easy, safe to use and extremely fast test for TB that is based on DNA detection. Current DNA-based detection of TB can take several hours. The PITBUL ultrafast TB test will be cost-effective and affordable for poor communities with high TB burden. The test will be used at the Point of Care, meaning settings where people infected with TB will first seek diagnosis, like hospitals, clinics and community centers.
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 768889. To find our more, visit: